By Technology Networks –
Chimeric antigen receptor (CAR) T cell therapy represents a breakthrough in cancer treatment. By harnessing the body’s immune system, CAR T therapy provides a powerful, personalized treatment option that can be particularly effective for treating blood cancers like leukemia—potentially offering patients a second chance at life when other treatments have failed.
However, despite its potential, nearly half of patients with leukemia relapse, and many experience serious side effects. Scientists have struggled to improve these treatments, in part because conventional testing methods fall short.
Now, a collaborative multidisciplinary team of researchers from the Perelman School of Medicine at the University of Pennsylvania and the Tandon School of Engineering at New York University has developed a miniature device that could transform how blood cancer treatments are tested and tailored for patients.
